PMC9701777_01
Changes of skin lesions and itching scale during tofacitinib treatment.(A) Image of skin lesions and itching scale before patient started oral tofacitinib. (B) Image of skin lesions and itching scale when patient started oral tofacitinib. (C-E) Images of skin lesions and itching scale at week 2,4,6. (F) Image of skin lesions and itching scale at week 18.
CCID-15-2519-g0001.jpg
PMC9701777_01_CCID-15-2519-g0001.jpg
f0001
When she first came to our visit, she reported intermittent itching (Figure 1A) (peak pruritus was 6 of 10 on a numeric rating scale). Her face was more swollen and irritable (Figure 1B). After 2 weeks symptoms relieved a lot, swelling on her face reduced (Figure 1C). As we can see, only perioral erythema remained and the patient reported middle itching (Figure 1D) (peak pruritus was 4 of 10 on a numeric rating scale. Finally, the skin lesions almost disappeared completely (Figure 1E) with occasionally itching (peak pruritus was 1 of 10 on a numeric rating scale and her mental health improved. She discontinued tofacitinib for 12 weeks without relapse of the eruption (Figure 1F).